PCV

COVID-19 Impact and Recovery Analysis- Automotive Positive Crankcase Ventilation (PCV) Valve Market 2019-2023 | Growth of Automotive Industry to Boost Growth | Technavio

Retrieved on: 
Thursday, May 7, 2020
Technology, Hardware, Automotive Manufacturing, Manufacturing, Crankcase ventilation system, PCV, Technology, Crankcase, Benchmarking, Articles

Our automotive positive crankcase ventilation (PCV) valve market report covers the following areas:

Key Points: 
  • Our automotive positive crankcase ventilation (PCV) valve market report covers the following areas:
    This study identifies the development of camless engine technology as one of the prime reasons driving the automotive positive crankcase ventilation (PCV) valve market growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the automotive positive crankcase ventilation (PCV) valve market, including some of the vendors such as Aisan Industry Co. Ltd., Ford Motor Co., General Motors Co., Sogefi Spa, and Tenneco Inc.
  • Backed with competitive intelligence and benchmarking, our research reports on the automotive positive crankcase ventilation (PCV) valve market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

The global automotive positive crankcase ventilation (PCV) valve market at a CAGR of almost 4% during the forecast period

Retrieved on: 
Monday, August 26, 2019
Machines, Crankcase ventilation system, Crankcase, PCV, Transport, Automotive aftermarket, Vehicles

NEW YORK, Aug. 26, 2019 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p05807363/?utm_source=PRN

Key Points: 
  • NEW YORK, Aug. 26, 2019 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p05807363/?utm_source=PRN
    This automotive positive crankcase ventilation (PCV) valve market analysis considers sales from both aftermarket and OEM.
  • Our analysis also considers the sales of automotive positive crankcase ventilation (PCV) valve in APAC, Europe, North America, South America, and MEA.
  • Also, our global automotive positive crankcase ventilation (PCV) valve market report looks at factors such as the growth of the automotive industry in emerging countries, increasing demand for premium vehicles, and adoption of new or improved emission standards.
  • With the presence of several major players, the global automotive positive crankcase ventilation (PCV) valve market is moderately fragmented.

Global Automotive Positive Crankcase Ventilation (PCV) Valve Market 2019-2023 | Development of Camless Engine Technology to Boost Growth | Technavio

Retrieved on: 
Tuesday, August 13, 2019
Other Manufacturing, Automotive, Technology, General Automotive, Manufacturing, Other Technology, Engines, Crankcase ventilation system, Camless piston engine, Crankcase, PCV

View the full release here: https://www.businesswire.com/news/home/20190813005453/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190813005453/en/
    Technavio has published a new market research report on the global automotive positive crankcase ventilation valve market during 2019-2023.
  • Global Automotive Positive Crankcase Ventilation Valve Market: Development of Camless Engine Technology
    Camless engine technology is gaining immense popularity in the automotive landscape.
  • Thus, the development of camless engine technology will fuel the growth of the automotive PCV valve market.
  • Global Automotive Positive Crankcase Ventilation Valve Market: Segmentation Analysis
    This market research report segments the global automotive positive crankcase ventilation valve market by sales channel (aftermarket and OEM), and geographic regions (North America, Europe, APAC, South America, and MEA).

Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants

Retrieved on: 
Wednesday, May 8, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, FDA, General Health, Vaccines, Medical specialties, Pneumonia, Medicine, Bacteria, Vaccination, Pneumococcal conjugate vaccine, Conjugate vaccine, PCV, Streptococcus pneumoniae, Immunogenicity, Pneumococcal polysaccharide vaccine

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2 trial ( NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114, the companys investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2 trial ( NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114, the companys investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age.
  • The FDAs decision was informed in part by immunogenicity data from this Phase 2 study, V114-008, and the Phase 1/2 V114-005 study in healthy adults and infants.
  • These Phase 2 data evaluating V114 in infants are encouraging and mark important progress to helping expand protection against pneumococcal disease for this vulnerable patient population.
  • V114 is Mercks investigational 15-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of pneumococcal disease in adults and children.